### 2.2.1 In vitro and physicochemical data

A literature search was performed to collect available information on physicochemical properties of Coproporphyrin-I. The obtained information from literature is summarized in the table below, and is used for model building.

| **Parameter**           | **Unit** | **Value** | Source                               | **Description**                                              |
| :---------------------- | -------- | --------- | ------------------------------------ | ------------------------------------------------------------ |
| MW                      | g/mol    | 654.71    | [Yoshikado 2018](#5-references)        | Molecular weight                                             |
| pK<sub>a</sub> (acid)   |          | 3.56      | [Yoshikado 2018](#5-references)         | acid dissociation constant of conjugate acid                 |
| pK<sub>a</sub> (base)   |          | 5.18      | [Yoshikado 2018](#5-references)         | acid dissociation constant of conjugate base                 |
| Solubility (pH7.4)      | mg/mL    | 0.03     | [DrugBank](#5-references)              | Aqueous Solubility in pH 7.4                 |
| logP                    |          | 2.53     | [Yoshikado 2018](#5-references)         | Partition coefficient between octanol and water              |
| fu                      | %        | 0.66       | [Yoshikado 2018](#5-references)   | Fraction unbound in plasma                                   |
| K<sub>m</sub> OATP1B1   | µmol/L   | 0.13    | [Bednarczy 2016](#5-references)            | OATP1B1 Michaelis-Menten constant                             |
| K<sub>m</sub> BCRP      | µmol/L   | 7.7      | [Gilibili 2017](#5-references)| BCRP Michaelis-Menten                                    |
| Synthesis rate        | nmol/h/kg  | 0.19     | [Mochizuki 2022](#5-references)          | Endogenous synthesis rate              |
| Renal clearance           | L/h/kg | 0.04     | [Mochizuki 2022](#5-references)        | elimination rate via kidneys             |

### 2.2.2 Clinical data

A literature search was performed to collect available clinical data on Coproporphyrin-I in adults. 

The following publications were found in adults for model building:

| Publication                   | Arm / Treatment / Information used for model building        |
| :---------------------------- | :----------------------------------------------------------- |
| [Mori 2020](#5-references)  | Baseline PK profiles in healthy subjects of Coproporphyrin-I|
| [Takehara 2018](#5-references) | Baseline and DDI plasma PK profiles in healthy subjects of Coproporphyrin-I|
| [Lai 2016](#5-references)   | Baseline and DDI plasma PK profiles in healthy subjects of Coproporphyrin-I|
| [Zhang 2020](#5-references)   | Baseline and DDI plasma PK profiles in healthy subjects of Coproporphyrin-I|


The following dosing scenarios were simulated and compared to respective data for model verification:

| Scenario                                                     | Data reference                       |
| ------------------------------------------------------------ | ------------------------------------ |
| DDI with 150 mg, 300 mg and 600 mg rifampicin                    |[Mori 2020](#5-references)           |


